Cannabis Use Disorder: Peer-Reviewed Research Consensus

30 studies analyzedLast updated March 7, 2026

Overview

The research base for cannabis use disorder includes 30 peer-reviewed studies spanning 2025–2026. Of these, 10 provide strong evidence, including 0 meta-analyses and 0 randomized controlled trials. Key findings with strong support include: a machine learning model using just five factors — sex, delinquency, and three personality traits — predicted cannabis use disorder within 5 years of first use, validated across three datasets, and nearly 1. However, several findings remain debated, and the evidence is not uniform across all areas. Many studies have methodological limitations including small sample sizes, short follow-up periods, and reliance on self-reported data.

What the Research Shows

Findings supported by multiple peer-reviewed studies. Stronger evidence means more consistency across study types.

A machine learning model using just five factors — sex, delinquency, and three personality traits — predicted cannabis use disorder within 5 years of first use, validated across three datasets

Moderate Evidence
10 studies|Based on limited number of strong-evidence studies.

Nearly 1

Moderate Evidence
10 studies|Based on limited number of strong-evidence studies.

Where Scientists Disagree

Areas where research shows conflicting results or ongoing scientific debate.

Among 420 teen cannabis users, using multiple product types (flower, concentrates, edibles) was the strongest predictor of cannabis use disorder at 6 months — stronger than any single product type

Moderate Evidence
6 studies|Southern California specific — may not generalize to regions with different cannabis markets. Self-reported use and CUD screening (not diagnosis). Short 6-month follow-up. Cannot determine if poly-pro

Analysis of a cannabis cessation app revealed distinct user profiles: coping-motivated users showed the most problematic use, suggesting digital interventions should personalize content based on why people use cannabis

Moderate Evidence
6 studies|App users are self-selected and may not represent all cannabis users. Cross-sectional — cannot track whether app use led to behavior change. Cluster analysis is exploratory. Specific to one app in a S

Researchers successfully adapted tobacco dependence measures to cannabis, creating a reliable 15-item scale that enables direct comparison of dependence across both substances for the first time

Moderate Evidence
6 studies|Single sample from a longitudinal study — may not represent all cannabis users. Adaptation from tobacco measures may miss cannabis-specific dependence features. Self-report only. Cross-sectional valid

National survey data showing psilocybin and LSD use associated with approximately double the risk of cannabis use disorder, complicating therapeutic psychedelic narratives

Moderate Evidence
6 studies|Cross-sectional design — people who use psychedelics may simply be more likely to use cannabis heavily for reasons unrelated to the psychedelic experience. Cannot distinguish therapeutic from recreati

What We Still Don't Know

  • Only 0 randomized controlled trials exist out of 30 studies — most evidence is observational or from reviews.
  • Sex-specific differences in this area remain understudied.
  • Long-term prospective studies tracking outcomes over 5+ years are largely absent from the literature.
  • Research on diverse populations (different ages, ethnicities, and medical backgrounds) remains limited.

Evidence Breakdown

Distribution of study types in this research area. Higher-tier evidence (meta-analyses, RCTs) provides stronger conclusions.

Observational & Cohort(Tier 3-4)
11 (37%)
Reviews & Scoping(Tier 4)
2 (7%)
Other
17 (57%)

Key Studies

The most impactful research in this area.

Why There's Still No FDA-Approved Medication for Cannabis Addiction

Cannabis use disorder affects millions but has zero FDA-approved treatments — understanding why the pipeline is stuck is essential for breaking through to effective medications.

2026

Using Cannabis in More Ways Dramatically Increases Risk of Addiction and Harm

Cannabis product diversification means young people can now use in many ways — this study shows the number of modes is an independent risk marker, not just a proxy for more frequent use.

2026

The Genetics of Trying Cannabis Are Different from the Genetics of Cannabis Addiction

The genetic distinction between trying cannabis and developing addiction is crucial — it means different people need different prevention approaches, and trying cannabis alone isn't a genetic pathway to addiction.

2026

Up to 1 in 5 People With Anxiety Disorders Also Have Cannabis Use Disorder

As cannabis becomes more accessible, understanding who is most vulnerable to problematic use is critical. People with anxiety disorders may use cannabis to cope but are at meaningful risk of developing dependence, creating a cycle that worsens both conditions.

2026

Cannabis Use Disorder Rising Dramatically Among Aging Veterans with HIV

As people with HIV live longer on antiretroviral therapy, rising cannabis use disorder in this aging population is concerning because cannabis can interact with many prescription medications these patients take.

2026

Cannabis Use Disorder Is Now the World's Most Prevalent Drug Use Disorder

Published in Nature Medicine, this comprehensive global analysis reveals that cannabis use disorder has become the world's most common drug use disorder, with legalization policies associated with higher rates across all substance categories.

2026

Research Timeline

How our understanding of this topic has evolved.

2020–present

30 studies published. Includes 10 strong-evidence studies.

About This Consensus

This consensus synthesizes 30 peer-reviewed studies: 11 observational studies (37%), 2 reviews (7%), 17 other study types (57%). Studies span from the earliest available research through 2025. Evidence strength ratings reflect study design, sample size, and replication across multiple research groups.

This page synthesizes findings from 30 peer-reviewed studies. It is not medical advice. Always consult a healthcare provider for personal health decisions.